Drug Search Results
More Filters [+]

Halothane

Alternative Names: halothane, fluothane
Latest Update: 2020-12-16
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: NMDA Antagonist,Potassium Channel Activator,GABA Modulator

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Australia | Bangladesh | Brazil | Canada | Chile | Colombia | Dominican Republic | Egypt | Germany | India | Indonesia | Ireland | Italy | Jordan | Malaysia | Morocco | New Zealand | Pakistan | Peru | Portugal | Russia | Slovenia | South Africa | Sri Lanka | Sweden | Taiwan | Tunisia | Turkey | United Kingdom | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Halothane

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title